BR112021017874A2 - Forma cristalina de um derivado de avibactam - Google Patents

Forma cristalina de um derivado de avibactam

Info

Publication number
BR112021017874A2
BR112021017874A2 BR112021017874A BR112021017874A BR112021017874A2 BR 112021017874 A2 BR112021017874 A2 BR 112021017874A2 BR 112021017874 A BR112021017874 A BR 112021017874A BR 112021017874 A BR112021017874 A BR 112021017874A BR 112021017874 A2 BR112021017874 A2 BR 112021017874A2
Authority
BR
Brazil
Prior art keywords
crystalline form
avibactam derivative
crystalline
avibactam
derivative
Prior art date
Application number
BR112021017874A
Other languages
English (en)
Inventor
Sami Karaborni
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of BR112021017874A2 publication Critical patent/BR112021017874A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

forma cristalina de um derivado de avibactam. a presente invenção refere-se a uma forma cristalina de um derivado de avibactam (1), ou seja, anidrato de 3(((((1r,2s,5r)-2-carbamoil-7-oxo-1,6-diazabiciclo[3.2.1]octan-6-il)óxi)sulfonil)óxi)-2,2-dimetilpropanoato de etila cristalino (i), a composições farmacêuticas do mesmo, e ao uso do derivado de avibactam cristalino para o tratamento de infecções bacterianas.
BR112021017874A 2019-03-12 2020-03-10 Forma cristalina de um derivado de avibactam BR112021017874A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817243P 2019-03-12 2019-03-12
PCT/US2020/021795 WO2020185729A1 (en) 2019-03-12 2020-03-10 Crystalline form of an avibactam derivative

Publications (1)

Publication Number Publication Date
BR112021017874A2 true BR112021017874A2 (pt) 2021-12-07

Family

ID=70155371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017874A BR112021017874A2 (pt) 2019-03-12 2020-03-10 Forma cristalina de um derivado de avibactam

Country Status (11)

Country Link
US (1) US11008321B2 (pt)
EP (1) EP3938366A1 (pt)
JP (1) JP2022524118A (pt)
KR (1) KR20210137159A (pt)
CN (1) CN113614084A (pt)
AU (1) AU2020237440B2 (pt)
BR (1) BR112021017874A2 (pt)
CA (1) CA3133071A1 (pt)
MX (1) MX2021011026A (pt)
SG (1) SG11202108905UA (pt)
WO (1) WO2020185729A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210186983A1 (en) * 2019-12-20 2021-06-24 Arixa Pharmaceuticals, Inc. Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033061A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
DK2562155T3 (da) 2010-04-20 2019-06-24 Fujifilm Toyama Chemical Co Ltd Hydroxaminsyrederivat
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
HUE032491T2 (en) 2010-12-22 2017-09-28 Meiji Seika Pharma Co Ltd An optically active diaza-bicyclooctane derivative and a process for its preparation
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
AR086590A1 (es) 2011-05-30 2014-01-08 Sumitomo Chemical Co Compuestos de ciclohexanona y herbicidas que los comprenden
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2016039432A1 (ja) 2014-09-12 2016-03-17 富山化学工業株式会社 新規なヒドロキサム酸誘導体および抗菌性物質を組み合わせて使用する方法
US10149911B2 (en) 2014-09-12 2018-12-11 Toyama Chemical Co., Ltd. Pharmaceutical composition containing hydroxamic acid derivative or salt thereof
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CN107531709B (zh) 2015-09-16 2020-10-23 吉林四环制药有限公司 β-内酰胺酶抑制剂及其用途
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN111448182A (zh) 2017-10-02 2020-07-24 阿里萨制药有限公司 氨曲南衍生物及其用途

Also Published As

Publication number Publication date
WO2020185729A1 (en) 2020-09-17
AU2020237440A1 (en) 2021-09-09
KR20210137159A (ko) 2021-11-17
US20200291022A1 (en) 2020-09-17
EP3938366A1 (en) 2022-01-19
SG11202108905UA (en) 2021-09-29
MX2021011026A (es) 2021-10-13
CA3133071A1 (en) 2020-09-17
US11008321B2 (en) 2021-05-18
JP2022524118A (ja) 2022-04-27
CN113614084A (zh) 2021-11-05
AU2020237440B2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
DK3625233T5 (da) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoat-derivativer og relaterede forbindelser som peroralt indgivne prodrugs af beta-lactamase-inhibitorer til behandling af bakterielle infektioner
BRPI0923326A2 (pt) Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto.
ECSP066667A (es) Derivados de ciclohexano espirociclicos
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
BR112018075297A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana
CL2021002263A1 (es) Compuestos antibacterianos (solicitud divisional 202001147)
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BR112021023927A2 (pt) Composto, e, composição farmacêutica
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
BR112021017874A2 (pt) Forma cristalina de um derivado de avibactam
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112013024497A2 (pt) novo derivado de oxazolidinona e composição farmacêutica incluindo o mesmo
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas
BR112022006507A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3
BRPI0719939B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]